



1. Home (<https://www.gov.uk/>)
2. Health and social care (<https://www.gov.uk/health-and-social-care>)
3. Medicines, medical devices (<https://www.gov.uk/health-and-social-care/medicines-medical-devices-blood>)

Press release

## **MHRA awarded over £980,000 for collaboration with the Bill and Melinda Gates Foundation and the World Health Organisation**

MHRA today announced a partnership worth over £980,000 to improve the safety monitoring of medicines in low and middle-income countries.

From:

Medicines and Healthcare products Regulatory Agency (<https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency>)

Published

15 December 2017



Medicines &  
Healthcare products  
Regulatory Agency

We are delighted to announce a new partnership with the Bill & Melinda Gates Foundation and the World Health Organisation that aims to extensively improve the safety monitoring of medicines in low and middle-income countries (LMIC).

New medicines and vaccines, for diseases such as malaria and HIV, may be introduced for the first time in LMIC's where there are weak or no regulatory systems in place for effective safety monitoring. These new treatments have been developed with urgent public health needs in mind and therefore the need to gather and analyse information quickly on their safety and effectiveness is important. The healthcare and regulatory systems in these settings may often lack the tools, training and capacity to operate a robust safety monitoring system. Whilst great progress has been made with many of LMIC's now involved as members of the World Health Organization Program for International Drug Monitoring, the experience in collecting, assessing and acting on adverse reaction data, and risk management planning is limited.

Without an effective system, public health programs are at risk and patients may be affected, should they suffer from adverse drug reactions (ADRs) which are not promptly identified and treated. This can consequently undermine the program and result in a loss of trust in the product or a vaccine. Ultimately, this may lead to lower uptake and therefore, the disease not being effectively treated.

WHO and the Gates Foundation have launched 'Project Smart Safety Surveillance' (also known as Project 3-S) to help LMIC's identify, assess, and adequately manage the risks associated with new products. MHRA will be joining this initiative to bring regulatory expertise to the project. This will be for a 3-year period where it is intended to run three pilot exercises in different LMIC settings.

Dr Ian Hudson, Chief Executive Officer at MHRA said:

We are delighted to be involved in such an important global initiative. New drugs and vaccines are being brought to the market for the first time in public health programmes in settings where the safety monitoring and regulatory systems need strengthening. The expertise we can bring to the project will help national safety monitoring centres identify risks and benefits early and take appropriate regulatory action to support global health.

Dr Dan Hartman of the Bill and Melinda Gates Foundation said:

The Triple S project is vitally important to the success of public health programmes to combat some of the world's major diseases. When a new medicine or vaccine is being used it is critical that potential risks are identified early and well understood. The involvement of MHRA in this project will ensure scientific and regulatory expertise are developed within the national centres.

Dr Ian Hudson discusses a new partnership with the Bill & Melinda Gates Foundation and the World Health Organisation (<https://www.youtube.com/watch?v=NdhsN3BBIpQ&feature=youtu.be>)

Media enquiries

News centre  
MHRA  
10 South Colonnade  
London  
E14 4PU

Email [newscentre@mhra.gov.uk](mailto:newscentre@mhra.gov.uk)

During office hours: 020 3080 7651 (08:30 - 17:00)

Out of office hours: 07770 446 189 (17:00 - 08:30)

Office hours are Monday to Friday, 8:30am to 5pm. For real-time updates including the latest press releases and news statements, see our Twitter channel at <https://www.twitter.com/mhragovuk> (<https://www.twitter.com/mhragovuk>)

Published 15 December 2017

## Related content

- Report of the Commission on Human Medicines Expert Working Group on Optimising Data on Medicines used During Pregnancy (<https://www.gov.uk/government/publications/report-of-the-commission-on-human-medicines-expert-working-group-on-optimising-data-on-medicines-used-during-pregnancy>)
- Report of the Commission on Human Medicines' Expert Working Group on Hormone Pregnancy Tests (<https://www.gov.uk/government/publications/report-of-the-commission-on-human-medicines-expert-working-group-on-hormone-pregnancy-tests>)
- Safer Medicines in Pregnancy and Breastfeeding Consortium (<https://www.gov.uk/government/publications/safer-medicines-in-pregnancy-and-breastfeeding-consortium>)
- Epilepsy medicines and pregnancy (<https://www.gov.uk/government/publications/epilepsy-medicines-and-pregnancy>)

## Brexit

Check what you need to do (<https://www.gov.uk/brexit>)

## Explore the topic

- Medicines, medical devices (<https://www.gov.uk/health-and-social-care/medicines-medical-devices-blood>)
- Public health (<https://www.gov.uk/health-and-social-care/public-health>)

## Is this page useful?

- Yes this page is useful

- 

Thank you for your feedback

## Help us improve GOV.UK

Don't include personal or financial information like your National Insurance number or credit card details.

What were you doing?

What went wrong?

## Help us improve GOV.UK

To help us improve GOV.UK, we'd like to know more about your visit today. We'll send you a link to a feedback form. It will take only 2 minutes to fill in. Don't worry we won't send you spam or share your email address with anyone.

Email address